Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ASXL3 | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
mRNA | CIPC | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | EPHA10 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
mRNA | ZCCHC2 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | RMND5A | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
mRNA | SLC25A16 | CTRPv2 | pan-cancer | AAC | -0.13 | 4e-05 |
mRNA | ZBTB8B | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | TSR3 | CTRPv2 | pan-cancer | AAC | -0.13 | 5e-05 |
mRNA | TMEM151B | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-05 |
mRNA | FAM184B | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |